Literature DB >> 8150770

Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. The Canadian Antimicrobial Resistance Study Group.

B W Toye1, S R Scriver, D E Low.   

Abstract

Increasing antimicrobial resistance has been reported for Klebsiella spp. and Enterobacter spp. The in-vitro activities of 14 antimicrobial agents against 656 clinical isolates of Klebsiella spp. and 630 isolates of Enterobacter spp. collected from seven cities in Canada were determined by microbroth dilution. There was no regional variation in the susceptibility patterns. Klebsiella spp. remain highly susceptible to most antimicrobials, only one isolate was resistant to third-generation cephalosporins. However, many isolates of Enterobacter spp. (> 16%) were resistant to the third-generation cephalosporins with marked cross-resistance to piperacillin (63.1%), piperacillin/tazobactam (44.9%), and aztreonam (76.6%). Gentamicin, tobramycin, imipenem, ciprofloxacin, cefepime, and cefpirome were consistently active against most isolates of Enterobacter spp. including those resistant to the third-generation cephalosporins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8150770     DOI: 10.1093/jac/32.suppl_b.81

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  Enterobacter spp.: pathogens poised to flourish at the turn of the century.

Authors:  W E Sanders; C C Sanders
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

Review 2.  Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia.

Authors:  L R Wiseman; H M Lamb
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 3.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

4.  Comparative activity of several antimicrobial agents against nosocomial Gram-negative rods isolated across Canada.

Authors:  S R Scriver; D E Low
Journal:  Can J Infect Dis       Date:  1995-03

5.  Canadian ciprofloxacin susceptibility study: comparative study from 15 medical centers. Canadian Ciprofloxacin Study Group.

Authors:  J M Blondeau; Y Yaschuk
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

6.  Canadian Multicenter Susceptibility Study, with a focus on cephalosporins, from 15 Canadian medical centers. The Canadian Multicenter Study Group.

Authors:  J M Blondeau; Y Yaschuk
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

Review 7.  Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; H M Bryson
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

Review 8.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.